Dr. David Roth
and begin RARA agent for patients Nancy, with IRFX in first that or I’ll biomarkers. RAR our a on positive our to with a alpha everyone in as call. being the today agonist is and II selective combination are SY-XXXX, class, morning MDS, good trial who for Thanks, higher-risk evaluated Phase AML
found durable in azacitidine. the combined to azacitidine the than and combination and Haematologica, provides published At European safety and assessments peer-reviewed deeper, clinical we we’ll agents, Association, with response leading focus agent in alone. the evaluating a induced that diagnosed to AML on ASH, on mechanism seen as XXXX’s patients. patients; of activity more with and in strong or preclinical apoptotic based the MDS of Hematology Specifically, supporting in be agent XXXX clinical biomarker-positive is combinations research combination with higher-risk and is and action with sharing Journal death biomarker-positive biological and we which which XXXX as factors: SY-XXXX rationale both initial daratumumab of combination azacitidine patients, patients. its cell for October, profile, and and combination the synergies a in XXXX with HMAs mechanistic In including in on MDS either azacitidine preclinical are This tolerability strategy and several its AML newly data We relapsed daratumumab and unfit daratumumab. efficacy agent refractory a single AML our with a DNA damage with with unique the hypomethylating
Additionally, in both plan patients. see the induction on for in that cohorts to we we arm, the is share ongoing. Enrollment level daratumumab CDXX data of
increased Given activity the opening in U.S. additional including unfit development in the speed months. measures, newly and population, we’re recent and diagnosed sites in sites implemented in enrollment, we’ve clinical by progress to opening in especially Europe AML, the our encouraged patient
clinical As group, the the of evaluable this in have X XX including responses. are week, of XX patients combination in we enrolled azacitidine for biomarker-positive cohorts, whom
the XX data available have biomarker-positive enrolled clinical for patients these X evaluable X We are of cohort, are daratumumab whom on patients responses. of and in
a selective treating is now that me on clinical potential in CDKX to We Now trial a XXXX ovarian Phase many SY-XXXX. turn I inhibition our let is of breast types. new CDKX cancers. for cancers focused tremendous and as approach has first-in-class inhibitor believe
Unlike BCLX. has or treat now cyclin-dependent hijack refractory transcription the processes, proteins the benefit. cycle been instance, MCLX of as cells has the CDKX At and a preclinical and as cell While XXXX therapeutic has which cell’s transcription breast CDKs anti-apoptotic In those progress are cycle. which including are CDKX blocks cancer, cell expression to an lower approved and kinases, to proven and XXXX dual X selectively and the exploited well drug studies, target established time, CDKX, of in CDKX as oncogenic shown often CDKs, area are proliferate. the activation and cancer therapeutic cell CDKs, to compelling activity such been has XXXX such treatment-resistant cycle. to models, MYB has selectively to ability research, difficult affording CDKX/X these unchecked cancer for survive critical of MYC of factors and targeting cell relapsed role same X, historically of a cycle as we the medicines numerous inhibiting for can anti-tumor and Preclinically, through not shown By cancer in cancers.
selective this All of to patients cancers profound a CDKX for up be large could we with inhibitors a provide benefit treatment believe with of what a that have existing approaches. for to adds eluded range opportunity
from to Meeting. at oral we’re the I Triple November the mentioned, Nancy dose-escalation on portion an Thursday, XX be really presenting of data Phase upcoming presentation trial the in As excited
any As evaluating is safety an as of on a these proof portion of data data on based engagements study PK patients data dose-escalation markers XXXX. solid the include advanced represent reminder, open The important which will tumors PD the as gene We and for well and target histology. was to believe mechanism, of milestone of with presentation expression.
has clinical been CDKX of of in whether the to Given toxicities, XXXX selective shown history key have even non-selective doses. CDK significant which studies, proof a but a inhibitors, be hampered at for achieve question mechanism tolerable by able would inhibitor been have activity which
agent focus receptor the of and inhibitor-resistant designed hormone safety positive portion cohorts cancer. in are of the of XXXX on study. both a combination relapsed as with ovarian enrolling single further patients or a breast We in The to and agent cancers metastatic expansion efficacy refractory patients and evaluate X now a CDKX/X expansion is the
We patients cohort for solid are an XXXX’s accessible further were also additional tumors, biopsies to enrolling and of who mechanism action. with evaluate
rationale activity offer these new cancer XXXX ovarian need preclinical ovarian are data demonstrated breast breast refractory which I pro-apoptotic for cancers. on There’s and for and of underscoring supporting in For cancers, in and ovarian the of efficacy focus with relapsed initial robust, ongoing breast care of carboplatin or mechanistic or therapies metastatic a models and investigation treatment Phase existing with fulvestrant, cancers. HR-positive limited patients cancer, including anti-proliferative options has therapies. the standard XXXX with our also
for associated data CDKX/X RB Triple suggests pathway. to data serous our rationale for for programs. know to in between clinical-stage look resistance that in models. are progress. both XXXX, RB ovarian alterations Syros, in cancer. you and of an mechanism keeping on presenting that with two RB are And I the a data with to alterations thirds the alterations pathway the readouts patients quarter The forward high-grade breast we Our also be be the emerging XXXX key At on in we’ll ovarian fourth have cancer our Meeting, cancer promises to inhibitors of synergy, updated preclinical carboplatinum mechanistic productive sensitivity the and time
over our for from updates and that, I’ll turn So efforts. pipeline Eric? call with preclinical the discovery Eric to
